3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Metabolic Solutions Development Company
ClinicalTrials.gov Identifier:
NCT01374438
First received: June 14, 2011
Last updated: November 5, 2014
Last verified: November 2014

June 14, 2011
November 5, 2014
July 2011
March 2013   (final data collection date for primary outcome measure)
Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum [ Time Frame: Days 1(baseline) and 91 ] [ Designated as safety issue: No ]
Investigate the effect of 150 mg daily MSDC-0160 vs placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis referenced to cerebellum, including five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex. Results are reported as Standardized Uptake Value Ratios. A change from baseline in the metabolic rate of glucose that is ≥0 indicates maintenance of brain glucose utilization, whereas values <0 indicate a decline in brain glucose utilization.
Change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis [ Time Frame: Days 1(baseline) and 91 ] [ Designated as safety issue: No ]
Estimate of the effect size of 150 mg daily MSDC-0160 versus placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis. The a priori regions of interest (ROI) will include five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex.
Complete list of historical versions of study NCT01374438 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Global Cognitive Function Tests [ Time Frame: Days 1 (baseline) and 91 ] [ Designated as safety issue: No ]
    Change from baseline in cognitive function, as determined by global cognitive function on a neuropsychological battery of 19 tests, following 3 months treatment with MSDC-0160 versus placebo. A summary measure of global cognitive function was constructed by converting raw scores from 19 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.
  • Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale [ Time Frame: Days 1 (baseline) and 91 ] [ Designated as safety issue: No ]
    Alzheimer's Disease Assessment Scale - Cognitive Subscale, an assessment of cognitive ability. Scores on 11 individual tasks were summed to produce the reported total score, with a possible range of 0 (no impairment) to 70 (severe impairment).
  • Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale [ Time Frame: Days 1 (baseline) and 91 ] [ Designated as safety issue: No ]
    Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. A summary measure of executive function was constructed by converting raw scores from 9 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.
  • Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks [ Time Frame: Days 1(baseline) and 91 ] [ Designated as safety issue: No ]
    Estimate the effect of 150 mg daily MSDC-0160 versus placebo on levels of high molecular weight adiponectin. Increases in HMW adiponectin suggest improved insulin sensitivity.
  • FDG-PET voxel-based analysis [ Time Frame: Days 1 (baseline) and 91 ] [ Designated as safety issue: No ]
    Estimate of the effect size of MSDC-0160 versus placebo on 3-month change in brain glucose utilization, using FDG-PET voxel-based analysis
  • Cognitive function tests [ Time Frame: Days 1 (baseline), 91, and 121 ] [ Designated as safety issue: No ]
    Estimate of the effect size of MSDC-0160 treatment versus placebo on 3-month change in cognitive function as determined by global cognitive function on a neuropsychological battery of 19 tests.
  • Cognitive function as determined by the ADAS-Cog subscale [ Time Frame: Days 1 (baseline), 91 and 121 ] [ Designated as safety issue: No ]
    Estimate of the effect size of MSDC-0160 versus placebo on 3-month change in cognitive function as determined by the ADAS-Cog subscale.
  • Cognitive function as estimate with the executive function scale [ Time Frame: Days 1 (baseline) and 91 ] [ Designated as safety issue: No ]
    Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale.
  • Correlation between baseline peripheral inflammatory biomarkers, genotype, and brain glucose utilization [ Time Frame: Days 1 (baseline) and 91 ] [ Designated as safety issue: No ]
    Explore whether baseline levels of peripheral inflammatory biomarkers (HMW adiponectin, TNFα, IL-6, hsCRP, and FFA) or genotypes including, but not limited to, the apolipoprotein ε4 allele explain the heterogeneity in baseline level of brain glucose utilization and, in MSDC-0160 users, 3-month brain glucose utilization.
  • Relationship between peripheral inflammatory biomarkers and brain glucose utilization. [ Time Frame: Days 1 (baseline) and 91 ] [ Designated as safety issue: No ]
    Explore whether changes in peripheral inflammatory biomarkers correlate with 3 month changes in brain glucose utilization in MSDC-0160 users.
  • Safety and tolerability of MSDC-0160 in this population [ Time Frame: Day 1 (baseline) through Day 121 (follow-up) ] [ Designated as safety issue: No ]
    Investigate the safety and tolerability of MSDC-0160 using reports of early study termination and adverse events.
Not Provided
Not Provided
 
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease

This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease. Safety and tolerability of MSDC-0160 in this population will also be studied. These results will be used to design larger studies of MSDC-0160 in persons with mild Alzheimer's disease.

The specific objective is to examine the feasibility of conducting future large scale studies on the efficacy of MSDC-0160 in persons with mild Alzheimer's disease. Efficacy and safety will be assessed as follows:

  1. Estimate the effect size of 150 mg daily MSDC-0160 versus placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis. The a priori regions of interest (ROI) will include five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex.
  2. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in brain glucose utilization, using FDG-PET voxel-based analysis.
  3. Estimate the effect size of MSDC-0160 treatment versus placebo on 3-month change in cognitive function as determined by global cognitive function on a neuropsychological battery of 19 tests.
  4. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in cognitive function as determined by the ADAS-Cog subscale.
  5. Estimate the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale.
  6. Explore whether baseline levels of peripheral inflammatory biomarkers (HMW adiponectin, TNFα, IL-6, hsCRP, and FFA) or genotypes including, but not limited to, the apolipoprotein ε4 allele explain the heterogeneity in baseline level of brain glucose utilization and, in MSDC-0160 users, 3-month brain glucose utilization.
  7. Explore whether changes in peripheral inflammatory biomarkers correlate with changes in 3-month brain glucose utilization in MSDC-0160 users.
  8. Investigate the safety of MSDC-0160 versus placebo using reports of early study termination and adverse events.
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Alzheimer's Disease
  • Drug: MSDC-0160
    MSDC-0160 150 mg capsules given once daily for 90 days
    Other Name: Mitoglitazone
  • Drug: Placebo
    Placebo capsules given once daily for 90 days
  • Experimental: MSDC-0160 capsules
    MSDC tablets contained in #00 capsules
    Intervention: Drug: MSDC-0160
  • Placebo Comparator: Placebo capsules
    Placebo tablets contained in #00 capsules
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
29
May 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or females 55-85 years of age.
  2. Females should be either postmenopausal or surgically sterilized. Males with female partners of child-bearing potential must use contraception if engaging in sexual intercourse.
  3. Diagnosis of probable Alzheimer's disease based on NIA-AA criteria with MMSE scores of 20 or greater.
  4. Willing and able to take part in up to six study visits over a 5-month period, with the support of a caregiver as needed.
  5. Willing and able to sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study, with the support of a caregiver as needed.

Exclusion Criteria:

  1. Diagnosis of diabetes, including use of anti-diabetic medications, or fasting plasma glucose >125 mg/dl or Hemoglobin A1c>6.4%.
  2. Unable to participate in FDG-PET scanning, including:

    • Inability to cooperate/claustrophobia (no sedation offered for this protocol).
    • Inability to lie still on the scanner bed for 40 minutes.
    • Total radiation dose exposure to the subject in any given year exceeds the limits of annual and total dose commitment of 50 mSv (5 REMs). The two FDG-PET scans will result in an approximate exposure of 10 mSv (1 REM).
  3. Diagnosis of significant neurological/psychiatric disease other than AD, including, but not limited to, any of the following: vascular dementia according to NINDS-AIREN criteria, space occupying cerebral lesion, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, and seizures.
  4. History of heart failure (including CHF).
  5. Previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 6 months prior to screening.
  6. Inability to undergo a clinical (1.5T) MRI of the brain without contrast and lack of a usable (less the 12 months prior to screening) MRI on record. Contraindications to undergoing an MRI of the brain include, but are not limited to, pacemakers; implantable cardioverter defibrillators; cochlear implants; cerebral aneurysm clips; implanted infusion pumps; implanted nerve stimulators; metallic splinters in the eye; and, other magnetic, electronic or mechanical implants or clinical findings that in the judgment of the investigator would pose a potential hazard in combination with MRI.
  7. ALT and/or AST levels that are twice the upper limit of normal; bilirubin levels that exceed 2 mg/dL; serum creatinine >1.5 mg/dL in men or > 1.4 mg/dL in women.
  8. Current or history of severe or unstable disorder (medical or psychiatric) requiring treatment that may make the subject unlikely to complete the study.
  9. Malignancy (other than non-melanoma skin cancer) within the last 5 years.
  10. Known history of HIV, hepatitis B, or hepatitis C.
  11. Blood pressure greater than 160/100 mmHg. Subjects with elevated BP will be allowed at the discretion of the principal investigator. Individuals with hypertension must have been stabilized to the current treatment regimen for at least 6 weeks prior to screening and not need adjustments to their treatment regimen during the entire study period.
  12. Change in other medications to treat Alzheimer's disease within 3 months prior to screening. Change in medication to treat other conditions within 6 weeks prior to screening or during the study period.
  13. Known or suspected intolerance or hypersensitivity to the study drugs, closely related compounds, or any of their stated ingredients.
  14. History of alcohol or drug abuse within 6 months of screening.
  15. Have participated in an investigational study or received an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to study drug administration.
  16. Single 12-lead ECG demonstrating a QTcB >450 msec or other clinically significant finding at screening. A single repeat ECG may be done at the investigator's discretion.
  17. Any surgical or medical condition which may significantly alter the absorption of any drug substance including, but not limited to, any of the following: history of major gastrointestinal tract surgery, currently active inflammatory bowel syndrome.
  18. Evidence of clinically relevant pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk.
Both
55 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01374438
MSDC-0160-C006
No
Metabolic Solutions Development Company
Metabolic Solutions Development Company
Not Provided
Study Director: Jerry R Colca, PhD MSDC
Principal Investigator: Raj C. Shah, MD Rush Memorial University Medical Center
Metabolic Solutions Development Company
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP